Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior part

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that

Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mix

Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to O

Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Com

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, includi

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, includi

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an ann

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) a

Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with Trans

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with Trans

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinolo

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintain

Brent climbed after new U.S.-Iran strikes, pushing the 10-year yield to a 19-month high; Edison and

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and low

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the pri

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the pr

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pha

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting Bi

Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a glo

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an ann

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Out

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting a

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the p

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raise

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lower

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, incl

Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55